CAMBRIDGE, Mass. & NEW ORLEANS--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced a collaboration with Ochsner Health ...

Collaboration expands national initiative designed to accelerate the discovery, validation, and delivery of non-invasive neuroprotective therapies Cognito Therapeutics, a late clinical-stage ...

Since the reversal of Roe v. Wade in 2022, anti-abortion rights advocates have continuously pursued laws and court cases to make access to abortion more difficult. A report published Tuesday finds ...

How many close friendships are enough? Are three to five ideal? Can one best friend be all you need? How about a dozen? “The more, the merrier,” says Vincent Day, who has separate clusters of close ...

New to this trend is Abdul Carter, who after a rookie season wearing No. 51 has announced that he is now No. 3, a number worn in 2025 by quarterback Russell Wilson. The trio of Giants pass rushers are ...

Abdul Carter's jersey number saga has reached a new checkpoint. Carter, who wore No. 51 during his rookie season with the Giants, is changing to No. 3, the team announced Friday. Carter's jersey ...

Jenny doesn’t live here anymore. The 1980s one-hit wonder “867-5309/Jenny” was so relentlessly drilled into the heads of MTV viewers that even younger generations know the digits by heart — and that’s ...

New findings highlight correlations between EEG and clinical outcome measures in Alzheimer’s disease Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive ...

Washington’s hottest commodity is a 10-digit number that can swing financial markets, drive the news, and shift policy—but only if the timing is right. The White House has received reports in recent ...

Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in $105 million in an oversubscribed series C funding round. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cambridge company is on its ...